Increasing public attention has recently been paid to the opioid epidemic and attendant effects on prenatally exposed infants and children. 1 Current literature has emerged proposing marijuana as a safe alternative to opioids in addressing pain 2 and cannabis legalization as a way to decrease opioid fatalities. 3 As a result, perceptions of cannabis safety have increased, and the prevalence of marijuana use among pregnant women has expanded; past-month cannabis use among pregnant US women increased from 2.4% to 3.9% between 2002 and 2014. 4 Further, cannabis potency has been substantially increasing over the past 4 decades in the United States, and will likely continue to do so as extraction procedures of active components improve.Although cannabis does have known medical utility for some conditions, its associated acute and longterm psychoactive effects on brain function are also known. Expanding use of cannabis among pregnant and lactating women (as likely will occur with legalization) may lead to increased risk from fetal and child exposures if the teratogenic potential of cannabis remains underappreciated.Delta-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana (1 of more than 500 components, 104 of which are cannabinoids), crosses the placental barrier readily. Accumulating evidence in animals and humans indicates that prenatal